Peptimmune, Inc.

Merck Serono's future prospects in the multiple sclerosis market look even less impressive following its decision to drop a Phase II multiple sclerosis candidate that it licensed from Japanese firm On

Merck Serono has signed two collaboration agreements with Japan's Ono Pharmaceutical with a view to strengthening two of its franchises, those covering multiple sclerosis (MS) and cancer. The first ag

In Vitro Diagnostics Mergers & Acquisitions /In Vitro Diagnostics Alere Inc. VitaPath Genetics Inc. Diagnostics company Alere Inc. has licensed global marketing rights to VitaPath Genetics Inc.

Merck Serono has paid $1.5 million for PI-2301, a peptide copolymer that its now bankrupt former owner Peptimmune described as a "next-generation Copaxone". The asset had previously been optioned to N